glp-1 receptor agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research Free Comparison Chart: GLP-1 and
Description
Pharmacol Rev 65(2):710778
Zhang X, Tang S, Zhang Q, et al
The SDUD are updated quarterly
A medication that helps with weight loss AND reduces systemic inflammation AND improves cardiovascular markers addresses multiple aspects of the lupus burden simultaneously
The trial focused on: Percentage of body weight lost Changes in blood sugar levels Shifts in blood pressure Tolerability at different doses, including the highest dose Safety over a longer treatment period This approach helped determine how the Eli Lilly weight-loss study compares to earlier GLP-1 research
